GroupAccess > Drug Coverage Guidelines

You are not signed in.

myBlueCross for Members
Forgot Username?
Forgot Password?

New to GroupAccess?

 

Search by Drug Name

  

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Product Name Implementation Date Guideline
DANAZOL 04/01/12 Prior authorization for medical necessity is required.
DAYTRANA® 06/12/06 The limits are 1 patch per day.
DEMEROL 01/01/13 The limits are 8 tablets per day for 50 mg and 100 mg tablets. Demerol 50 mg/5 mL solution has a limit of 80 mL/day.
DESVENLAFAXINE SR 24HR 07/01/13 The limits are 1 tablet per day.
DEXILANT" 07/01/10 Dexilant may be subject to step therapy requirements. Patients must have trial and failure of generic lansoprazole, omeprazole, pantoprazole, or rabeprazole. The limits are 1 tablet per day.
DIABENESE 04/01/12 The limits are 60 tablets per 30 days for 100mg and 90 tablets per 30 days for 250mg.
DIABETA 04/01/12 The limits are 30 tablets per 30 days for 1.25mg and 2.5mg tablets, and 120 tablets per 30 days for 5mg tablets.
DIDANOSINE 07/01/12 The limits are 1 capsule per day.
DIFFERIN® 04/01/01 Prior authorization for medical necessity may be required.
DILAUDID 01/01/13 The limits are 6 tablets per day or 48 mL/day for the Dilaudid 1 mg/mL solution.
DIOVAN HCT® 01/01/11 Diovan HCT may be subject to step therapy requirements. Patients must have trial and failure of both of the following: 1) generic ACE inhibitor or generic ARB, AND 2) preferred brand ARB (Diovan, Exforge/HCT, Micardis/HCT).
DIOVAN® 01/01/11 Diovan may be subject to step therapy requirements. Patients must have trial and failure of a generic ACE Inhibitor or generic ARB.
DOLGIC PLUS 04/01/13 The limits are 5 tablets per day.
DOLOPHINE 01/01/13 The limits are 3 tablets per day.
DORYX® 11/14/07 Doryx may be subject to step therapy requirements. Patients must have trial and failure of generic immediate release doxycycline.

1 2